Future Sustained Drug Delivery Methods for Choroidal Neovascularization

During the American Academy of Ophthalmology’s Retina Subspecialty Day in 2015, Peter K. Kaiser, MD, described six alternative methods being looked at for delivery of anti-VEGF drugs into the retinas of individuals experiencing choroidal neovascularization (CNV). Periodic intraocular injections are currently the only procedure for halting damaging blood vessel growth and leakage. Injections are expensive, time-consuming, and burdensome on the patients, so [Read More]

Long-term Treatment for Wet AMD Enters Phase 2 Trials

Neurotech Pharmaceuticals, Inc. has announced that they have enrolled the first patient in their multicenter Phase 2 clinical trial of NT-503 Encapsulated Cell Therapy (ECT) for the long-term treatment of wet macular degeneration (AMD). NT-503 is a unique vascular endothelial growth factor (VEGF) receptor protein continuously produced by Neurotech’s versatile ECT implant. “This landmark proof-of-concept [Read More]

Low Vision Conferences Becoming High-Tech Accessible

Organizations for the blind and visually impaired will soon be able to provide indoor navigation technology at their national conferences. The service, called “Audio Guide”, is being offered free gratis to charitable organizations by Macular Degeneration Support, with financial backing by Macular Degeneration Foundation. Beginning in 2015, conference attendees will be able to more easily [Read More]

Making artificial vision look more natural

Courtesy: National Eye Institute, National Institutes of Health (NEI/NIH) NIH-funded study could help improve retinal prosthetic devices In laboratory tests, researchers have used electrical stimulation of retinal cells to produce the same patterns of activity that occur when the retina sees a moving object. Although more work remains, this is a step toward restoring natural, [Read More]